4D Molecular Therapeutics (NASDAQ:FDMT) Posts Earnings Results, Misses Estimates By $0.10 EPS

4D Molecular Therapeutics (NASDAQ:FDMT) announced its quarterly earnings results on Friday. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10), Zacks reports.

4D Molecular Therapeutics Stock Performance

Shares of 4D Molecular Therapeutics stock traded up $0.05 during trading hours on Friday, reaching $4.53. The company’s stock had a trading volume of 1,233,187 shares, compared to its average volume of 846,836. 4D Molecular Therapeutics has a one year low of $4.20 and a one year high of $36.25. The company has a market capitalization of $209.41 million, a P/E ratio of -1.59 and a beta of 2.81. The stock’s fifty day simple moving average is $5.22 and its two-hundred day simple moving average is $8.59.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on FDMT shares. Morgan Stanley dropped their price objective on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a report on Monday, January 13th. BMO Capital Markets downgraded shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $40.00 to $15.00 in a report on Monday, January 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, February 19th. Royal Bank of Canada reduced their price objective on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th. Finally, Chardan Capital reduced their price objective on shares of 4D Molecular Therapeutics from $39.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday, February 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $32.13.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.